Expert ELISA and immunoassay solutions for impurity detection and quantitative analysis.
We help biopharmaceutical teams develop, optimize, and validate robust impurity ELISAs — from early development through commercialization.
Host cell protein, residual Protein A, insulin, and other process-related impurity assays sit at the center of regulatory scrutiny. Poor sensitivity, non-parallelism, matrix interference, or weak antibody coverage can delay programs, trigger comparability questions, or derail validation timelines.
These challenges require more than standard method development — they require specialized expertise.
Focused Expertise in Impurity ELISAs
Quantera BioAnalytics provides strategic scientific consultation for impurity assay development across the biopharmaceutical lifecycle.
We specialize in:
Host Cell Protein (HCP) ELISAs
Residual Protein A assays
Insulin and other product-related impurities
Assay troubleshooting & rescue
Phase-appropriate validation planning
Regulatory defense strategy
Early scientific intervention prevents costly validation delays and regulatory risk.
Schedule a Consultation Today